(±) -Lisofylline
(±) -Lisofylline ((±) -Lisophylline) is the racemate of Lisofylline. Lisofylline inhibits the generation of phosphatidic acid and free fatty acids. Lisofylline also blocks the release of pro-inflammatory cytokines in oxidative tissue injury, in response to cancer chemotherapy and in experimental sepsis. Lisofylline can be used for Type 1 diabetes research[1].
Product Specifications
CAS Number
6493-06-7
Product Name Alternative
(±) -Lisophylline
UNSPSC
12352005
Hazard Statement
H302-H315-H319-H335
Target
Interleukin Related
Type
Reference compound
Related Pathways
Immunology/Inflammation
Applications
Metabolism-sugar/lipid metabolism
Field of Research
Metabolic Disease; Inflammation/Immunology
Assay Protocol
https://www.medchemexpress.com/racemic-lisofylline.html
Concentration
10mM
Purity
99.93
Solubility
DMSO : 100 mg/mL (ultrasonic)
Smiles
O=C(N1CCCCC(O)C)N(C)C2=C(N(C)C=N2)C1=O
Molecular Formula
C13H20N4O3
Molecular Weight
280.33
Precautions
P261-P264-P270-P271-P280-P302+P352-P304+P340-P330-P362+P364-P405-P501
References & Citations
[1]Yang Z, et al. Lisofylline: a potential lead for the treatment of diabetes. Biochem Pharmacol. 2005 Jan 1;69 (1) :1-5.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Available Sizes
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
Recombinant Human GNB1L Protein, GST, E.coli-50ug